拜瑞妥治疗静脉血栓的效果

Rivaroxaban (rivaroxaban) is a highly selective, oral drug that directly inhibits factor xa. Rivaroxaban was jointly developed by Bayer Pharma of Germany and Johnson & Johnson of the United States. In October 2008, it was approved for marketing in Canada and the European Union under the trade name Xarelto.

Rivaroxaban is a drug that prevents and treats venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism in patients after hip and knee replacement surgery (ChemicalbookPE). It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome.

EINSTEIN-Jr is a randomized, open-label Phase III study enrolling 500 pediatric patients (birth to 17 years) diagnosed with acute VTE who were initiated on heparin therapy. Pediatric patients received open-label, weight-adjusted dose Xarelto (n = 335, tablet or suspension) or standard anticoagulant therapy (n = 165, unfractionated heparin, low-molecular-weight heparin, fondaparinux, or a switch to a vitamin K antagonist) in a 2:1 ratio. The treatment period is 3 months, except for children under 2 years of age with catheter-related VTE who receive 1 month of treatment. Repeat imaging was performed at the end of treatment. The results showed that the study met all pre-specified endpoints: recurrent VTE events were similar in the 2 groups, and slightly lower in the rivaroxaban () treatment group (recurrent VTE event rate: 1.2% [n=4] vs 3.0% [n=5]; HR=0.40, 95%CI: 0.11-1.41), and no fatal VTE events occurred in either treatment group.

Recommended related hot articles: /newsDetail/81609.html